Table 1.
Patient and tumor characteristics
| Baseline characteristics | ||||
|---|---|---|---|---|
| Total | TP53 mutated | TP53 wild type | p-value | |
|
Patients (%) Age y, mean (range) |
354 63 (19–95) |
102 (29) 62 (21–95) |
254 (71) 64 (19–89) |
0.24 |
| Gender | 0.21 | |||
| Female (%) | 145 (41) | 36 (25) | 109 (75) | |
| Male (%) | 209 (59) | 66 (32) | 143 (68) | |
| WHO classification, 2016 (%) | ||||
| (D)LBCL (%) | 215 (61) | 65 (30) | 150 (70) | |
| Burkitt | 4 (1) | 4 (100) | 0 | |
| DLBCL, NOS | 167 (47) | 52 (31) | 115 (69) | |
| PCDLBCL LT | 13 (4) | 2 (15) | 11 (85) | |
| HGBL | 11 (3) | 5 (45) | 6 (55) | |
| PCNSL | 17 (5) | 2 (12) | 15 (88) | |
| PMBL | 3 (1) | 0 | 3 (100) | |
| MCL | 28 (8) | 16 (57) | 12 (43) | |
| IBCL (%) | 111 (31) | 21 (19) | 90 (81) | |
| NOS | 4 (1) | 1 (5) | 3 (95) | |
| FL | 52 (47) | 9 (45) | 43 (55) | |
| HCL | 2 (2) | 1 (50) | 1 (50) | |
| LPL | 12 (11) | 1 (8) | 11 (92) | |
| MALT | 8 (7) | 1 (13) | 7 (87) | |
| NMZL | 17 (15) | 1 (6) | 16 (94) | |
| CLL | 13 (12) | 6 (46) | 7 (54) | |
| PCFCL | 3 (3) | 1 (33) | 2 (67) | |
| Tissue | 0.11 | |||
| Primary | 252 (71) | 66 (26) | 186 (84) | |
| Secondary | 102 (29) | 36 (35) | 66 (65) | |
WHO, World Health Organization; (D)LBCL, (diffuse) large B-cell lymphoma; DLBCL, NOS, diffuse large B-cell lymphoma, not otherwise specified; PC DLBCL LT, primary cutaneous diffuse large B-cell lymphoma leg type; HGBL, high grade B-cell lymphoma; PCNSL, primary central nervous system lymphoma; PMBL, primary mediastinal B-cell lymphoma; MCL, mantle cell lymphoma; IBCL, indolent B-cell lymphoma; NOS, not otherwise specified; FL, follicular lymphoma; HCL, hairy cell lymphoma; LPL, lymphoplasmacytic lymphoma; MALT, mucosa-associated lymphoid tissue; NMZL, nodal marginal zone lymphoma; CLL, chronic lymphocytic lymphoma; PCFCL, primary cutaneous follicle centre lymphoma